The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Human Annexin A1 Protein Market Research Report 2025
Synopsis
Global Recombinant Human Annexin A1 Protein market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Human Annexin A1 Protein market research.
Key manufacturers engaged in the Recombinant Human Annexin A1 Protein industry include Abcam, Novus Biologicals, QED Bioscience, Elabscience, Assay Genie, Labome, Active Bioscience, Boster Bio and Lifespan Biosciences, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Recombinant Human Annexin A1 Protein were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Recombinant Human Annexin A1 Protein market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant Human Annexin A1 Protein market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abcam
Novus Biologicals
QED Bioscience
Elabscience
Assay Genie
Labome
Active Bioscience
Boster Bio
Lifespan Biosciences
RayBiotech
Protein Alternatives
enQuire BioReagents
Abeomics
Creative BioMart
KMD Bioscience
OriGene
MedChemExpress
Cusabio
Canvax
Biorbyt
Bon Opus Biosciences
Prospec Bio
Neuromics
Segment by Type
>85%
>90%
>95%
Others
Segment by Application
ELISA
WB
Antibody Production
Protein Array
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Human Annexin A1 Protein report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Global Recombinant Human Annexin A1 Protein market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Human Annexin A1 Protein market research.
Key manufacturers engaged in the Recombinant Human Annexin A1 Protein industry include Abcam, Novus Biologicals, QED Bioscience, Elabscience, Assay Genie, Labome, Active Bioscience, Boster Bio and Lifespan Biosciences, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Recombinant Human Annexin A1 Protein were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Recombinant Human Annexin A1 Protein market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant Human Annexin A1 Protein market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abcam
Novus Biologicals
QED Bioscience
Elabscience
Assay Genie
Labome
Active Bioscience
Boster Bio
Lifespan Biosciences
RayBiotech
Protein Alternatives
enQuire BioReagents
Abeomics
Creative BioMart
KMD Bioscience
OriGene
MedChemExpress
Cusabio
Canvax
Biorbyt
Bon Opus Biosciences
Prospec Bio
Neuromics
Segment by Type
>85%
>90%
>95%
Others
Segment by Application
ELISA
WB
Antibody Production
Protein Array
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Human Annexin A1 Protein report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Recombinant Human Annexin A1 Protein Market Overview
1.1 Product Overview and Scope of Recombinant Human Annexin A1 Protein
1.2 Recombinant Human Annexin A1 Protein Segment by Type
1.2.1 Global Recombinant Human Annexin A1 Protein Market Value Comparison by Type (2023-2029)
1.2.2 >85%
1.2.3 >90%
1.2.4 >95%
1.2.5 Others
1.3 Recombinant Human Annexin A1 Protein Segment by Application
1.3.1 Global Recombinant Human Annexin A1 Protein Market Value by Application: (2023-2029)
1.3.2 ELISA
1.3.3 WB
1.3.4 Antibody Production
1.3.5 Protein Array
1.3.6 Others
1.4 Global Recombinant Human Annexin A1 Protein Market Size Estimates and Forecasts
1.4.1 Global Recombinant Human Annexin A1 Protein Revenue 2018-2029
1.4.2 Global Recombinant Human Annexin A1 Protein Sales 2018-2029
1.4.3 Global Recombinant Human Annexin A1 Protein Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Recombinant Human Annexin A1 Protein Market Competition by Manufacturers
2.1 Global Recombinant Human Annexin A1 Protein Sales Market Share by Manufacturers (2018-2023)
2.2 Global Recombinant Human Annexin A1 Protein Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Recombinant Human Annexin A1 Protein Average Price by Manufacturers (2018-2023)
2.4 Global Recombinant Human Annexin A1 Protein Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Recombinant Human Annexin A1 Protein, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Human Annexin A1 Protein, Product Type & Application
2.7 Recombinant Human Annexin A1 Protein Market Competitive Situation and Trends
2.7.1 Recombinant Human Annexin A1 Protein Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Human Annexin A1 Protein Players Market Share by Revenue
2.7.3 Global Recombinant Human Annexin A1 Protein Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Human Annexin A1 Protein Retrospective Market Scenario by Region
3.1 Global Recombinant Human Annexin A1 Protein Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Recombinant Human Annexin A1 Protein Global Recombinant Human Annexin A1 Protein Sales by Region: 2018-2029
3.2.1 Global Recombinant Human Annexin A1 Protein Sales by Region: 2018-2023
3.2.2 Global Recombinant Human Annexin A1 Protein Sales by Region: 2024-2029
3.3 Global Recombinant Human Annexin A1 Protein Global Recombinant Human Annexin A1 Protein Revenue by Region: 2018-2029
3.3.1 Global Recombinant Human Annexin A1 Protein Revenue by Region: 2018-2023
3.3.2 Global Recombinant Human Annexin A1 Protein Revenue by Region: 2024-2029
3.4 North America Recombinant Human Annexin A1 Protein Market Facts & Figures by Country
3.4.1 North America Recombinant Human Annexin A1 Protein Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Recombinant Human Annexin A1 Protein Sales by Country (2018-2029)
3.4.3 North America Recombinant Human Annexin A1 Protein Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Human Annexin A1 Protein Market Facts & Figures by Country
3.5.1 Europe Recombinant Human Annexin A1 Protein Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Recombinant Human Annexin A1 Protein Sales by Country (2018-2029)
3.5.3 Europe Recombinant Human Annexin A1 Protein Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Human Annexin A1 Protein Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Human Annexin A1 Protein Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Recombinant Human Annexin A1 Protein Sales by Country (2018-2029)
3.6.3 Asia Pacific Recombinant Human Annexin A1 Protein Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Recombinant Human Annexin A1 Protein Market Facts & Figures by Country
3.7.1 Latin America Recombinant Human Annexin A1 Protein Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Recombinant Human Annexin A1 Protein Sales by Country (2018-2029)
3.7.3 Latin America Recombinant Human Annexin A1 Protein Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Human Annexin A1 Protein Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Human Annexin A1 Protein Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Recombinant Human Annexin A1 Protein Sales by Country (2018-2029)
3.8.3 Middle East and Africa Recombinant Human Annexin A1 Protein Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Human Annexin A1 Protein Sales by Type (2018-2029)
4.1.1 Global Recombinant Human Annexin A1 Protein Sales by Type (2018-2023)
4.1.2 Global Recombinant Human Annexin A1 Protein Sales by Type (2024-2029)
4.1.3 Global Recombinant Human Annexin A1 Protein Sales Market Share by Type (2018-2029)
4.2 Global Recombinant Human Annexin A1 Protein Revenue by Type (2018-2029)
4.2.1 Global Recombinant Human Annexin A1 Protein Revenue by Type (2018-2023)
4.2.2 Global Recombinant Human Annexin A1 Protein Revenue by Type (2024-2029)
4.2.3 Global Recombinant Human Annexin A1 Protein Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant Human Annexin A1 Protein Price by Type (2018-2029)
5 Segment by Application
5.1 Global Recombinant Human Annexin A1 Protein Sales by Application (2018-2029)
5.1.1 Global Recombinant Human Annexin A1 Protein Sales by Application (2018-2023)
5.1.2 Global Recombinant Human Annexin A1 Protein Sales by Application (2024-2029)
5.1.3 Global Recombinant Human Annexin A1 Protein Sales Market Share by Application (2018-2029)
5.2 Global Recombinant Human Annexin A1 Protein Revenue by Application (2018-2029)
5.2.1 Global Recombinant Human Annexin A1 Protein Revenue by Application (2018-2023)
5.2.2 Global Recombinant Human Annexin A1 Protein Revenue by Application (2024-2029)
5.2.3 Global Recombinant Human Annexin A1 Protein Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant Human Annexin A1 Protein Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Abcam
6.1.1 Abcam Corporation Information
6.1.2 Abcam Description and Business Overview
6.1.3 Abcam Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Abcam Recombinant Human Annexin A1 Protein Product Portfolio
6.1.5 Abcam Recent Developments/Updates
6.2 Novus Biologicals
6.2.1 Novus Biologicals Corporation Information
6.2.2 Novus Biologicals Description and Business Overview
6.2.3 Novus Biologicals Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novus Biologicals Recombinant Human Annexin A1 Protein Product Portfolio
6.2.5 Novus Biologicals Recent Developments/Updates
6.3 QED Bioscience
6.3.1 QED Bioscience Corporation Information
6.3.2 QED Bioscience Description and Business Overview
6.3.3 QED Bioscience Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.3.4 QED Bioscience Recombinant Human Annexin A1 Protein Product Portfolio
6.3.5 QED Bioscience Recent Developments/Updates
6.4 Elabscience
6.4.1 Elabscience Corporation Information
6.4.2 Elabscience Description and Business Overview
6.4.3 Elabscience Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Elabscience Recombinant Human Annexin A1 Protein Product Portfolio
6.4.5 Elabscience Recent Developments/Updates
6.5 Assay Genie
6.5.1 Assay Genie Corporation Information
6.5.2 Assay Genie Description and Business Overview
6.5.3 Assay Genie Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Assay Genie Recombinant Human Annexin A1 Protein Product Portfolio
6.5.5 Assay Genie Recent Developments/Updates
6.6 Labome
6.6.1 Labome Corporation Information
6.6.2 Labome Description and Business Overview
6.6.3 Labome Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Labome Recombinant Human Annexin A1 Protein Product Portfolio
6.6.5 Labome Recent Developments/Updates
6.7 Active Bioscience
6.6.1 Active Bioscience Corporation Information
6.6.2 Active Bioscience Description and Business Overview
6.6.3 Active Bioscience Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Active Bioscience Recombinant Human Annexin A1 Protein Product Portfolio
6.7.5 Active Bioscience Recent Developments/Updates
6.8 Boster Bio
6.8.1 Boster Bio Corporation Information
6.8.2 Boster Bio Description and Business Overview
6.8.3 Boster Bio Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Boster Bio Recombinant Human Annexin A1 Protein Product Portfolio
6.8.5 Boster Bio Recent Developments/Updates
6.9 Lifespan Biosciences
6.9.1 Lifespan Biosciences Corporation Information
6.9.2 Lifespan Biosciences Description and Business Overview
6.9.3 Lifespan Biosciences Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Lifespan Biosciences Recombinant Human Annexin A1 Protein Product Portfolio
6.9.5 Lifespan Biosciences Recent Developments/Updates
6.10 RayBiotech
6.10.1 RayBiotech Corporation Information
6.10.2 RayBiotech Description and Business Overview
6.10.3 RayBiotech Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.10.4 RayBiotech Recombinant Human Annexin A1 Protein Product Portfolio
6.10.5 RayBiotech Recent Developments/Updates
6.11 Protein Alternatives
6.11.1 Protein Alternatives Corporation Information
6.11.2 Protein Alternatives Recombinant Human Annexin A1 Protein Description and Business Overview
6.11.3 Protein Alternatives Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Protein Alternatives Recombinant Human Annexin A1 Protein Product Portfolio
6.11.5 Protein Alternatives Recent Developments/Updates
6.12 enQuire BioReagents
6.12.1 enQuire BioReagents Corporation Information
6.12.2 enQuire BioReagents Recombinant Human Annexin A1 Protein Description and Business Overview
6.12.3 enQuire BioReagents Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.12.4 enQuire BioReagents Recombinant Human Annexin A1 Protein Product Portfolio
6.12.5 enQuire BioReagents Recent Developments/Updates
6.13 Abeomics
6.13.1 Abeomics Corporation Information
6.13.2 Abeomics Recombinant Human Annexin A1 Protein Description and Business Overview
6.13.3 Abeomics Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Abeomics Recombinant Human Annexin A1 Protein Product Portfolio
6.13.5 Abeomics Recent Developments/Updates
6.14 Creative BioMart
6.14.1 Creative BioMart Corporation Information
6.14.2 Creative BioMart Recombinant Human Annexin A1 Protein Description and Business Overview
6.14.3 Creative BioMart Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Creative BioMart Recombinant Human Annexin A1 Protein Product Portfolio
6.14.5 Creative BioMart Recent Developments/Updates
6.15 KMD Bioscience
6.15.1 KMD Bioscience Corporation Information
6.15.2 KMD Bioscience Recombinant Human Annexin A1 Protein Description and Business Overview
6.15.3 KMD Bioscience Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.15.4 KMD Bioscience Recombinant Human Annexin A1 Protein Product Portfolio
6.15.5 KMD Bioscience Recent Developments/Updates
6.16 OriGene
6.16.1 OriGene Corporation Information
6.16.2 OriGene Recombinant Human Annexin A1 Protein Description and Business Overview
6.16.3 OriGene Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.16.4 OriGene Recombinant Human Annexin A1 Protein Product Portfolio
6.16.5 OriGene Recent Developments/Updates
6.17 MedChemExpress
6.17.1 MedChemExpress Corporation Information
6.17.2 MedChemExpress Recombinant Human Annexin A1 Protein Description and Business Overview
6.17.3 MedChemExpress Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.17.4 MedChemExpress Recombinant Human Annexin A1 Protein Product Portfolio
6.17.5 MedChemExpress Recent Developments/Updates
6.18 Cusabio
6.18.1 Cusabio Corporation Information
6.18.2 Cusabio Recombinant Human Annexin A1 Protein Description and Business Overview
6.18.3 Cusabio Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Cusabio Recombinant Human Annexin A1 Protein Product Portfolio
6.18.5 Cusabio Recent Developments/Updates
6.19 Canvax
6.19.1 Canvax Corporation Information
6.19.2 Canvax Recombinant Human Annexin A1 Protein Description and Business Overview
6.19.3 Canvax Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Canvax Recombinant Human Annexin A1 Protein Product Portfolio
6.19.5 Canvax Recent Developments/Updates
6.20 Biorbyt
6.20.1 Biorbyt Corporation Information
6.20.2 Biorbyt Recombinant Human Annexin A1 Protein Description and Business Overview
6.20.3 Biorbyt Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Biorbyt Recombinant Human Annexin A1 Protein Product Portfolio
6.20.5 Biorbyt Recent Developments/Updates
6.21 Bon Opus Biosciences
6.21.1 Bon Opus Biosciences Corporation Information
6.21.2 Bon Opus Biosciences Recombinant Human Annexin A1 Protein Description and Business Overview
6.21.3 Bon Opus Biosciences Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Bon Opus Biosciences Recombinant Human Annexin A1 Protein Product Portfolio
6.21.5 Bon Opus Biosciences Recent Developments/Updates
6.22 Prospec Bio
6.22.1 Prospec Bio Corporation Information
6.22.2 Prospec Bio Recombinant Human Annexin A1 Protein Description and Business Overview
6.22.3 Prospec Bio Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Prospec Bio Recombinant Human Annexin A1 Protein Product Portfolio
6.22.5 Prospec Bio Recent Developments/Updates
6.23 Neuromics
6.23.1 Neuromics Corporation Information
6.23.2 Neuromics Recombinant Human Annexin A1 Protein Description and Business Overview
6.23.3 Neuromics Recombinant Human Annexin A1 Protein Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Neuromics Recombinant Human Annexin A1 Protein Product Portfolio
6.23.5 Neuromics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Human Annexin A1 Protein Industry Chain Analysis
7.2 Recombinant Human Annexin A1 Protein Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Human Annexin A1 Protein Production Mode & Process
7.4 Recombinant Human Annexin A1 Protein Sales and Marketing
7.4.1 Recombinant Human Annexin A1 Protein Sales Channels
7.4.2 Recombinant Human Annexin A1 Protein Distributors
7.5 Recombinant Human Annexin A1 Protein Customers
8 Recombinant Human Annexin A1 Protein Market Dynamics
8.1 Recombinant Human Annexin A1 Protein Industry Trends
8.2 Recombinant Human Annexin A1 Protein Market Drivers
8.3 Recombinant Human Annexin A1 Protein Market Challenges
8.4 Recombinant Human Annexin A1 Protein Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
